Section 5 of 6
Economic information and modeling report
1 evidence topic · 2 sources
Modeling overview
Summary
The economic evidence in this report concerns broader mitochondrial disease populations rather than a budget impact model for SL1009. A U.S. claims study reported per member per month costs of $4,829 for pediatric participants and $3,100 for adults. An Australian study estimated annual average household costs of AU$112,721, with 92% attributable to societal costs. These estimates describe disease burden, not SL1009 acquisition costs, treatment-related cost offsets, or incremental budget impact. The report contains no SL1009-specific budget impact model.
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.